

Спеціалізований рецензований науково-практичний журнал для педіатрів та сімейних лікарів

Здоров'я[®] ДИТИНИ

Том 17, № 8, 2022

ISSN 2224-0551 (print), ISSN 2307-1168 (online)

ПЕРЕДПЛАТНИЙ ІНДЕКС
95264
www.mif-ua.com

ZASLAVSKY[®]
Publishing house



Дніпровський державний медичний університет
Донецький національний медичний університет



Здоров'я дитини
Child's Health

Спеціалізований рецензований науково-практичний журнал
Заснований в липні 2006 року
Періодичність виходу: 8 разів на рік

Том 17, № 8, 2022

Включений в наукометричні і спеціалізовані бази даних

Scopus,

НБУ ім. В.І. Вернадського, «Україніка наукова», «Наукова періодика України», JIC index, Ulrichsweb Global Serials Directory, CrossRef, WorldCat, Google Scholar, ICMJE, SHERPA/RoMEO, NLM-catalog, NLM-Locator Plus, OpenAIRE, BASE, ROAD, DOAJ, Index Copernicus, EBSCO, OUCI



mif-ua.com



Open Journal System

Зміст

Клінічна педіатрія

- Антипкін Ю.Г., Марушко Ю.В., Омельченко Л.І.,
Муквіч О.М., Людвік Т.А., Бондаренко Н.Ю.,
Бовкун О.А., Ісмакаєва Д.Л.
Стан кальцієвого гомеостазу
і окремі аспекти його порушень
при ювенільному ідіопатичному артриті..... 5
- Марушко Т.В., Куріліна Т.В., Кульчицька Є.-Е.Б.
Вплив дієти CHILD-1 на харчовий профіль
і дієтичний комплаєнс в українських
педіатричних пацієнтів із гетерозиготною
сімейною гіперхолестеринемією 12
- Леженко Г.О., Абатуров О.Є., Захарченко Н.А.
Патогенетична роль вітаміну D та вітамін
D-зв'язуючого білка в розвитку інфекції
сечовивідних шляхів у дітей..... 20

На допомогу педіатру

- Крамарьов С.О., Серякова І.Ю., Kolte Roohi,
Палатна Л.О., Євтушенко В.В.,
Камінська Т.М., Рязанських А.О.
Маски онкологічних захворювань
у практиці лікаря-інфекціоніста 25

Неонатологія

- Мавропуло Т.К., Власов О.О., Верещак О.Ю.
Діагностичні помилки в неонатології..... 33

Огляд літератури

- Марушко Ю.В., Дмитришин О.А., Гицак Т.В.,
Іовіца Т.В., Бовкун О.А.
Особливості методики проведення,
діагностична цінність та світові рекомендації
з оцінки толерантності до фізичного
навантаження у дітей (огляд літератури,
власні дослідження) 39

Випадок із практики

- Крючко Т.О., Бубир Л.М., Пода О.А., Несіна І.М.,
Коваленко Л.А., Матяж Д.С.
Труднощі діагностики гастроінтестинальної
алергії в педіатричній практиці:
клінічний випадок 49
- Синицька В.О., Боярчук О.Р., Грех О.І.
Клінічний випадок ускладненого перебігу
імуноглобулін-А-васкуліту з тривалим
нефритом: особливості лікування 54

Теоретична медицина

- Абатуров О.Є., Бабич В.Л.
Механізми дії екстрацелюлярних
мікроРНК 58

Contents

Clinical Pediatrics

- Yu.G. Antypkin, Yu.V. Marushko, L.I. Omelchenko,
O.M. Mukvich, T.A. Liudvik, N.Yu. Bondarenko,
O.A. Bovkun, D.L. Ismakajeva
Calcium homeostasis and certain
aspects of its disturbances
in juvenile idiopathic arthritis 5
- T. Marushko, T. Kurilina, Y.-E. Kulchytska
Impact of the Cardiovascular Health Integrated
Lifestyle Diet on nutritional profile and dietary
compliance in Ukrainian pediatric patients with
heterozygous familial hypercholesterolemia..... 12
- H.O. Lezhenko, O.Ye. Abatur, N.A. Zakharchenko
The pathogenetic role of vitamin D and vitamin
D-binding protein in the development of urinary
tract infection in children 20

To Help the Pediatrician

- S.O. Kramarov, I.Yu. Seriakova, Roohi Kolte,
L.O. Palatna, V.V. Yevtushenko, T.M. Kaminska,
A.O. Ryazanskikh
Masks of cancers in the practice
of an infectious disease doctor..... 25

Neonatology

- T.K. Mavropulo, O.O. Vlasov, O.Yu. Vereshchak
Diagnostic errors in neonatology 33

Review of Literature

- Yu.V. Marushko, O.A. Dmytryshyn, T.V. Hyshchak,
T.V. Iovitsa, O.A. Bovkun
Peculiarities of the methodology,
diagnostic value, and global
recommendations for assessing
exercise tolerance in children
(literature review, own research) 39

Case Report

- T.O. Kryuchko, L.M. Buby, O.A. Poda, I.M. Nesina,
L.A. Kovalenko, D.S. Matiazh
Difficulties in diagnosing
gastrointestinal allergy in paediatric
practice: a clinical case 49
- V.O. Synytska, O.R. Boyarchuk, O.I. Greh
A clinical case of a complicated course
of immunoglobulin A vasculitis with long-term
nephritis: peculiarities of treatment 54

Theoretical Medicine

- A.E. Abatur, V.L. Babych
Mechanisms of action
of extracellular miRNAs 58

The pathogenetic role of vitamin D and vitamin D-binding protein in the development of urinary tract infection in children

Abstract. Background. The aim of the research was to study the content of $1,25(\text{OH})_2\text{D}_3$ and vitamin D-binding protein (DBP) in the blood serum of children with urinary tract infections, taking into account the clinical form of the disease, and to determine their pathogenetic role in the development of urinary tract infections. **Materials and methods.** The study groups consisted of 84 children (mean age — 10.0 ± 1.3 years). The main group was divided into subgroups: the first one — 17 children with acute pyelonephritis, the second one — 21 patients with chronic pyelonephritis, the third one — 16 children with acute cystitis, the fourth one — 10 patients with unspecified urinary tract infections. The control group consisted of 20 relatively healthy children. The content of $1,25(\text{OH})_2\text{D}_3$ and DBP was investigated by immunoenzymatic analysis. **Results.** It was found that the development of the inflammatory process in the urinary tract was accompanied by a statistically significant ($p < 0.01$) decrease in the level of $1,25(\text{OH})_2\text{D}_3$ in the blood serum of the children of the main group compared to the controls. The level of $1,25(\text{OH})_2\text{D}_3$ in patients of all subgroups was significantly lower than that of the control group ($p < 0.01$), but there was no statistical difference between them. Serum level of DBP in the main group was statistically significantly ($p < 0.05$) increased compared to the controls, but we did not find a statistically significant difference between the subgroups studied. **Conclusions.** The development of an acute inflammatory process in the urinary tract in children occurs against the background of a statistically significant decrease in the blood level of $1,25(\text{OH})_2\text{D}_3$ combined with high levels of vitamin D-binding protein. This serves as a pathogenetic basis for the need to develop therapeutic and prophylactic schemes for prescribing vitamin D to children with urinary tract infections.

Keywords: children; urinary tract infection; vitamin D; vitamin D-binding protein

Introduction

Despite significant advances in diagnosis and therapy, urinary tract infections (UTIs) are still widespread bacterial infections of childhood [1], second only to respiratory diseases in terms of prevalence. Delay in diagnosis and appropriate therapy can lead to serious complications such as renal scarring, hypertension and chronic kidney disease [2]. At present, the issues of the peculiarities of the immune system functioning in children, which allowed the inflammatory bacterial process to develop in the urinary system, and in some cases even created the conditions for the chronicity of the UTI process, remain uncertain. It is suggested that

urinary tract protection may be highly dependent on specific soluble mediators derived from epithelial cells one of which is the bactericidal antimicrobial peptide cathelicidin, whose expression is stimulated by $1,25(\text{OH})_2\text{D}_3$ in epithelial cells, macrophages/monocytes, and neutrophils [3].

In recent years, several hundred reports on multicenter studies and meta-analyses dedicated to the study of the pathogenetic role of vitamin D in various pathological conditions have been conducted and published.

It is known that vitamin D is largely a regulator of innate immunity, although its classic functions are regulation of calcium-phosphorus homeostasis and control of bone

metabolism [4]. To date, many studies have focused on investigating the causes and consequences of reduced synthesis of $1,25(\text{OH})_2\text{D}_3$ by the kidneys. It has been shown that the active form of vitamin D_3 stimulates autophagy, which has become a factor and mechanism critical for the control of intracellular pathogens, while $1,25(\text{OH})_2\text{D}_3$ -induced expression of the antimicrobial peptide LL37, which has pronounced antimicrobial properties, is a key component of anti-inflammatory responses [5]. Cathelicidin has the ability to suppress the inflammatory cascade that occurs after the attachment of the pathogen to the uroepithelium, thus alleviating the severity of UTI [6]. Various authors have shown that $1,25(\text{OH})_2\text{D}_3$ inhibits the expression of Toll-like receptors on monocytes and the production of some inflammatory cytokines, such as interleukin (IL) 2, IL-6 and IL-17 [7]. Vitamin D deficiency can cause hypocalcemia, which, in turn, reduces the activity of neutrophils and lymphocytes [6]. All this suggests that the active form of vitamin D, $1,25(\text{OH})_2\text{D}_3$, is able to control immune function at different levels.

Because vitamin D is highly lipophilic, there is an urgent need for serum protein carriers to ensure efficient delivery to target cells [8]. One of these is vitamin D-binding protein (DBP). DBP is mainly synthesized by liver parenchymal cells and expressed in several tissues, including liver, kidney, gonads, fat, and neutrophils. As a rule, it performs a transport function for various ligands and participates in the regulation of immune and inflammatory processes [9]. Due to the high ability to bind vitamin D and its metabolites, it regulates their bioavailability, increasing biological half-life and protecting them from hydroxylase-mediated catabolism [9]. Alshahawey M. (2021) notes that DBP is not affected by vitamin D levels, but is regulated by estrogen, glucocorticoids, and inflammatory cytokines [10]. Typically, only 1–2 % of the total circulating pool of DBP has bound vitamin D, and this percentage never rises above 5 % [11]. Against this background, the literature contains a certain number of works on the direct effect of DBP on the immune reactions [10, 12, 13].

So, this prompted us to study the role of vitamin D and DBP in children with UTI.

The purpose: to study the content of $1,25(\text{OH})_2\text{D}_3$ and DBP in the blood serum of children with urinary tract infections, taking into account the clinical form of the disease, and to determine their pathogenetic role in the development of urinary tract infections.

Materials and methods

We examined 84 children aged 6 to 14 years (the mean age was 10.0 ± 1.3 years) who were hospitalized to the Zaporizhzhia Regional Children's Clinical Hospital in 2018–2020. The main study group included 64 children with primary urinary tract infections. Patients with urinary tract abnormalities, as well as those who received antibacterial therapy prior to the experiment, were excluded from the study. The children were divided into groups depending on the classification and taking into account the criteria for the diagnosis of UTI, according to the EAU guidelines, 2021 (levels of evidence I, II) [14], and the order of the Ministry of Health of Ukraine No. 627 dated 03.11.2008 [15].

The main group children were divided into four sub-groups: the first included 17 children with acute pyelonephritis, the second — 21 patients with chronic pyelonephritis, the third — 16 children with acute cystitis, the fourth — 10 patients with unspecified urinary tract infections. The control group included 20 relatively healthy children, representative by sex and age, without any inflammatory signs of the urinary system.

The serum $1,25$ -dihydroxyvitamin D and DBP concentrations in patients included in the study were detected by enzyme-linked immunosorbent assay (ELISA) using a commercial kit by Immunodiagnostic Systems, $1,25(\text{OH})_2\text{D}_3$ EIA (UK) and Human DBP ELISA Kit (Elabscience, USA), respectively.

The results obtained were processed by the method of variation statistics using statistical packages Excel and Statistica 13.0 (StatSoft Inc., No. JPZ8041382130ARCN10-J). The method of correlation analysis with the calculation of Spearman's rank correlation coefficient was applied. The non-parametric Mann-Whitney test (U) was used to assess differences between indicators. Differences were considered significant at $p < 0.05$.

All human studies complied with the ethical standards of the Institutional and National Research Committee and the 1964 Declaration of Helsinki and its subsequent amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study. A complete set of data on children, their parents and physicians confirming the results of this study was not publicly available due to limited initial ethics approvals.

Results

The results of the research are presented in Fig. 1, 2.

As can be seen from the data shown in Fig. 1, the development of the inflammatory process in the urinary tract was accompanied by a predicted statistically significant




Figure 1. The content of $1,25(\text{OH})_2\text{D}_3$ in the blood serum of children with urinary tract infection who were under observation

(25.1 (24.0; 27.4) pg/ml, $p < 0.01$) decrease in the level of $1,25(\text{OH})_2\text{D}_3$ in the blood serum of children who were under our observation compared to the control group, where this indicator was 54.1 (52.6; 61.87) pg/ml.

In the process of further work with the actual material, we analyzed the content of $1,25(\text{OH})_2\text{D}_3$ in the blood serum of children from the observation groups. The results of the comparisons are presented in Table 1.

As expected, the level of $1,25(\text{OH})_2\text{D}_3$ in patients of all selected subgroups was significantly lower than that of the controls ($p < 0.01$), but without statistical difference between them. The obtained data indicate that vitamin D deficiency in children's blood serum may contribute to the development of UTI. The development of UTI might be a factor, which leads to increased utilization and subsequent deficiency of $1,25(\text{OH})_2\text{D}_3$, considering that vitamin D plays a regulatory role in the development of the innate immune response. In particular, $1,25(\text{OH})_2\text{D}_3$ promotes the synthesis of such antimicrobial peptides as cathelicidin and β -defensins under conditions of Toll-like receptors stimulation.

The next stage of our work was to study the level vitamin D-binding protein in the blood serum of children who were under our observation. This choice was due to the fact that DBP, in addition to its main function, i.e. the transport of

vitamin D metabolites, performs a number of other functions, specifically influencing the functioning of the immune system due to the activation of macrophages, participation in chemotaxis, etc. [16].

The obtained data showed a picture diametrically opposed to the one we observed during the analysis of the content of $1,25(\text{OH})_2\text{D}_3$.

As can be seen in Fig. 2, the development of the inflammatory process in the urinary tract was accompanied by a statistically significant ($p < 0.05$) increase in the serum level of DBP in children of the main group compared to the controls: 148.3 (136.8; 164.9) vs. 75.9 (17.5; 135.6) ng/ml, respectively.

Later, according to the design of this study, we investigated the content of DBP in the blood serum of children of selected subgroups. The obtained results are presented in Table 1.

It was found that the development of the inflammatory process in the urinary tract in children of all subgroups was accompanied by an increase in the level of DBP in the blood serum, but we did not find a statistically significant difference between the subgroups studied.

Discussion

At present, there is no doubt about the role of vitamin D in the implementation and regulation of the effects of innate and acquired immunity [17]. It has been proven that the immunomodulatory effect of vitamin D is realized by expressing its receptors on immune cells [18]. Thus, $1,25(\text{OH})_2\text{D}_3$ mediates the expression of antimicrobial peptides such as β -defensin and cathelicidin [19] an increased production of which, in turn, enhances the direct antibacterial effect on uropathogenic *E.coli* [20]. At the same time, the number of studies investigating the role of vitamin D in inflammatory diseases of the urinary system in children is quite limited. Li X. et al. (2021), Sadeghzadeh M. et al. (2021) demonstrated that the development of UTI occurred against the background of a low level of vitamin D in the blood serum. Hacıhamdioğlu D.Ö. et al. (2016) drew attention to the presence of vitamin D deficiency in the group of patients with UTI, they also noted that there was no significant difference between the serum vitamin D levels in patients with upper and lower UTI. The results of our work confirmed the stated data, namely, we noted a statistically significant ($p < 0.01$) decrease in the serum level of vitamin D in children with urinary tract infections compared to the control group, and did not find a significant difference between the levels of vitamin D in the studied subgroups.

On the other hand, in the modern literature there are some works in which the authors note an increased level of




Figure 2. DBP content in the blood serum of children with urinary tract infection who were under observation

Table 1. The content of $1,25(\text{OH})_2\text{D}_3$ and DBP in the blood serum of children with urinary tract infection depending on the clinical form of the disease

Indicators	Control group (n = 20)	Subgroup 1 (n = 17)	Subgroup 2 (n = 21)	Subgroup 3 (n = 16)	Subgroup 4 (n = 10)
$1,25(\text{OH})_2\text{D}_3$, pg/ml	54.1 (52.6; 61.87)	24.4 (24.1; 26.0)**	25.7 (24.0; 27.3)**	24.4 (22.9; 27.3)**	25.5 (24.8; 27.6)**
DBP, ng/ml	75.9 (17.5; 135.6)	161 (136.9; 171.4)**	146.4 (136.3; 163.1)*	147.3 (142.4; 157.7)*	143 (138.5; 163.2)*

Notes: * – $p < 0.05$ in comparison with the control group; ** – $p < 0.01$ in comparison with the control group.

vitamin D in patients with urinary tract infections. Thus, Mahyar A. et al. (2018) showed that the average level of 25(OH)D in the blood serum of children in the study group was significantly higher than in the control group. At the same time, there were no significant differences in the content of vitamin D in the blood serum of patients with acute pyelonephritis and cystitis. The authors recommend not prescribing additional vitamin D, as this may lead to an unregulated hyperactive immune response to infection, which, in turn, may be responsible for the increased risk of UTI [2].

At the same time, most authors point to vitamin D deficiency in inflammatory diseases of the urinary system [1, 20, 21]. Thus, Zasloff M. (2007) explained that with vitamin D deficiency, macrophages infected with bacterial agents cannot sufficiently induce expression of a number of antibacterial peptides. The lack of sufficient AMP synthesis creates conditions for the development and progression of UTI, and also deepens the severity of the disease [17, 22]. Thus, most authors point to the need for further development of both indications and schemes for the preventive and therapeutic use of vitamin D in UTI [6, 18, 20].

Vitamin D-binding protein has not become so widespread for research, although it was discovered in the 1960s. In the works of various authors, it is noted that deficiency or excess of vitamin D, resistance to vitamin D, idiopathic hypercalcemia in childhood, osteoporosis, and many other diseases do not affect the concentration of DBP in the blood serum [9, 23, 24]. These data appear logical, if we take into account the fact that only 5–10 % of the total amount of DBP is necessary for the transport of vitamin D metabolites to the point of realization of their biological effect [12]. DBP is a multifunctional protein. Its other functions include the ability to significantly enhance the chemotactic activity of chemoattractants of neutrophils; induce the selective recruitment of neutrophils; to absorb actin released from damaged or dead cells and to form DBP-actin complexes all of which underscore its important role during inflammation [11]. The given data explain the results we obtained, namely that the development of the inflammatory process in the urinary tract was accompanied by a statistically significant ($p < 0.05$) increase in the level of DBP in the blood serum of the children of the main group. During the literature data analysis, we noted that several authors have shown that the activation of neutrophils during inflammation increases their binding sites with DBP, which contributes to C5a-induced chemotaxis; however, binding of 1,25(OH)₂D₃, but not 25(OH)D₃ blocks DBP stimulation of C5a activity [23]. Additionally, Kew R.R. (2019) noted that 1,25(OH)₂D₃ has a direct inhibitory effect on the function of the chemotactic cofactor DBP for neutrophils due to binding to DBP at physiological concentrations. Bikle D.D. and Schwartz J. (2019) pointed out that some cytokines, such as IL-6, increase the production of DBP. In turn, in our previous work [23], it was shown that the development of an acute inflammatory process in the urinary tract of children occurs precisely against the background of a significant increase in the expression of the pro-inflammatory cytokine IL-6 in the blood serum. Apparently, the revealed feature was one of the causes for the high levels of DBP in children with UTI.

Thus, pleiotropic active metabolites of vitamin D in combination with DBP influence the reaction of protective non-specific mechanisms with the determination of the nature of the inflammatory process and the ability to eradicate the infectious agent [17]. At the same time, the problem is still far from being solved and requires further research.

Conclusions

1. The development of an acute inflammatory process in the urinary tract in children occurs against the background of a statistically significant decrease in the level of 1,25(OH)₂D₃ in the blood serum combined with high levels of vitamin D-binding protein.

2. The given data are the pathogenetic basis for the need to develop therapeutic and prophylactic schemes for the administration of vitamin D to prevent the occurrence and manage infectious diseases, including urinary tract infections in children.

References

1. Georgieva V., Kamolvit W., Herthelius M., Lüthje P., Brauner A., Chromek M. Association between vitamin D, antimicrobial peptides and urinary tract infection in infants and young children. *Acta Paediatrica*. 2018. 108(3). 551–6. doi: 10.1111/apa.14499.
2. Mahyar A., Ayazi P., Safari S., Dalirani R., Javadi A., Esmaeily S. Association between vitamin D and urinary tract infection in children. *Korean Journal of Pediatrics*. 2018. 61(3). 90. doi: 10.3345/kjp.2018.61.3.90.
3. Övünç Hacıhamdioğlu D., Altun D., Hacıhamdioğlu B., Çekmez F., Aydemir G., Kul M., Müftüoğlu T., Süleymanoğlu S., Karademir F. The association between serum 25-hydroxy vitamin D level and urine cathelicidin in children with a urinary tract infection. *Journal of Clinical Research in Pediatric Endocrinology*. 2016. 8(3). 325–9. doi: 10.4274/jcrpe.2563.
4. Sassi F., Tamone C., D'Amelio P. Vitamin D: nutrient, hormone, and immunomodulator. *Nutrients*. 2018. 10(11). 1656. doi: 10.3390/nu10111656.
5. Ismailova A., White J.H. Vitamin D, infections and immunity. *Reviews in Endocrine and Metabolic Disorders*. 2021. 23(2). 265–77. doi: 10.1007/s11154-021-09679-5.
6. Qadir S., Memon S., Chohan M.N., Memon Y. Frequency of vitamin-D deficiency in children with urinary tract infection: a descriptive cross-sectional study. *Pakistan Journal of Medical Sciences*. 2021. 37(4). doi: 10.12669/pjms.37.4.3896.
7. Charoengnam N., Holick M.F. Immunologic effects of vitamin D on human health and disease. *Nutrients*. 2020. 12(7). 2097. doi: 10.3390/nu12072097.
8. Chun R.F., Peercy B.E., Orwoll E.S., Nielson C.M., Adams J.S., Hewison M. Vitamin D and DBP: The Free Hormone Hypothesis revisited. *Journal of Steroid Biochemistry and Molecular Biology*. 2014. 144. 132–7.
9. Lisowska-Myjak B., Józwiak-Kisielewska A., Łukaszkiwicz J., Skarzyńska E. Vitamin D-binding protein as a biomarker to confirm specific clinical diagnoses. *Expert Review of Molecular Diagnostics*. 2019. 20(1). 49–56. doi: 10.1080/14737159.2020.1699064.
10. Alshahawey M. A genetic insight into vitamin D binding protein and COVID-19. *Medical Hypotheses*. 2021. 149. 110531. doi: 10.1016/j.mehy.2021.110531.
11. Kew R.R. The vitamin D binding protein and inflammatory injury: a mediator or sentinel of tissue damage? *Frontiers in Endocrinology*. 2019. 10. doi: 10.3389/fendo.2019.00470.

12. Chun R.F., Shieh A., Gottlieb C., Yacoubian V., Wang J., Hewison M., Adams J.S. Vitamin D binding protein and the biological activity of vitamin D. *Frontiers in Endocrinology*. 2019. 10. doi: 10.3389/fendo.2019.00718.
13. Xie Z., Wang X., Bikle D.D. Editorial: vitamin D binding protein, total and free vitamin D levels in different physiological and pathophysiological conditions. *Frontiers in Endocrinology*. 2020. 11. doi: 10.3389/fendo.2020.00040.
14. Hoen L., Bogaert G., Radmayr C., Dogan H., Nijman R., Quaedackers J., Rawashdeh Y., Silay M., Tekgul S., Bhat N., Stein R. Update of the EAU/ESPU guidelines on urinary tract infections in children. *European Urology*. 2021. 79. S446-S448.
15. [zakon.rada.gov.ua. Treatment protocol for children with urinary tract infections and tubulointerstitial nephritis. Available from: https://zakon.rada.gov.ua/rada/show/v0627282-08#Text \(in Ukrainian\).](https://zakon.rada.gov.ua/rada/show/v0627282-08#Text)
16. Raymond M.-A., Désormeaux A., Labelle A., Soulez M., Soulez G., Langelier Y. et al. Endothelial stress induces the release of vitamin D-binding protein, a novel growth factor. *Biochemical and Biophysical Research Communications*. 2005. 338(3). 1374-82.
17. Abaturov A.E., Kryuchko T.A., Lezhenko G.A., Zavgordnyaya N.Yu. *Antimicrobial peptides and proteins of the respiratory tract, diagnostic significance and therapeutic possibilities. Kharkiv: Planeta-Print, 2018 (in Russian).*
18. Sadeghzadeh M., Khoshnevisasl P., Motamed N., Faghfourli L. The serum vitamin D levels in children with urinary tract infection: a case-control study. *New Microbes and New Infections*. 2021. 43. 100911. doi: 10.1016/j.nmni.2021.100911.
19. Zendejdel A., Arefi M. Molecular evidence of role of vitamin D deficiency in various extraskelatal diseases. *Journal of Cellular Biochemistry*. 2019. 120(6). 8829-40. doi: 10.1002/jcb.28185.
20. Hertting O., Lüthje P., Sullivan D., Aspenström P., Brauner A. Vitamin D-deficient mice have more invasive urinary tract infection. *PLOS One*. 2017. 12(7). doi: 10.1371/journal.pone.0180810.
21. Li X., Yu Q., Qin F., Zhang B., Lu Y. Serum vitamin D level and the risk of urinary tract infection in children: a systematic review and meta-analysis. *Frontiers in Public Health*. 2021. 9. doi: 10.3389/fpubh.2021.637529.
22. Zasloff M. Antimicrobial peptides, innate immunity, and the normally sterile urinary tract. *Journal of the American Society of Nephrology*. 2007. 18(11). 2810-6. doi: 10.1681/ASN.2007050611.
23. Bikle D.D., Schwartz J. Vitamin D binding protein, total and free vitamin D levels in different physiological and pathophysiological conditions. *Frontiers in Endocrinology*. 2019. 10. doi: 10.3389/fendo.2019.00317.
24. Bouillon R., Schuit F., Antonio L., Rastinejad F. Vitamin D binding protein: a historic overview. *Frontiers in Endocrinology*. 2020. 10. doi: 10.3389/fendo.2019.00910.
25. Lezhenko H.O., Zakharchenko N.A. The pathogenetic role of some cytokines in the development and course of various clinical forms of urinary tract infections in children. *Zdorov'ya rebenka*. 2022. 17(3). 128-32. doi: 10.22141/2224-0551.17.3.2022.1507.

Received 01.12.2022

Revised 15.12.2022

Accepted 20.12.2022 ■

Information about authors

H. Lezhenko, MD, Professor, Head of the Department of Hospital Pediatrics, Zaporizhzhia State Medical University, Zaporizhzhia, Ukraine; e-mail: genalezh@gmail.com; <https://orcid.org/0000-0003-0851-4586>

O. Abaturov, MD, PhD, Professor, Head of the Department of Pediatrics 1 and Medical Genetics, Dnipro State Medical University, Dnipro, Ukraine; e-mail: alexabaturov@i.ua; <https://orcid.org/0000-0001-6291-5386>

N. Zakharchenko, MD, PhD Student of the Department of Hospital Pediatrics, Zaporizhzhia State Medical University, Zaporizhzhia, Ukraine; e-mail: natali_koms@ukr.net; <https://orcid.org/0000-0002-3956-8571>

Conflict of interests. Authors declare the absence of any conflicts of interests and own financial interest that might be construed to influence the results or interpretation of the manuscript.

Information about funding. The work was performed within the research work of the department "Predicting the course of the most common inflammatory diseases of childhood". State registration number 0121U107520.

Authors' contribution: Lezhenko H.O. — research concept and design; critical revision of the article; final approval of the article, Abaturov O.Ye. — final approval of the article, Zakharchenko N.A. — collection and assembly of data; data analysis and interpretation; writing the article.

Леженко Г.О.¹, Абатуров О.Є.², Захарченко Н.А.¹

¹Запорізький державний медичний університет, м. Запоріжжя, Україна

²Дніпровський державний медичний університет, м. Дніпро, Україна

Патогенетична роль вітаміну D та вітамін D-зв'язуючого білка в розвитку інфекції сечовивідних шляхів у дітей

Резюме. Мета роботи. Дослідити вміст 1,25(OH)₂D₃ та вітамін D-зв'язуючого білка (DBP) у сироватці крові дітей з інфекціями сечовидільної системи залежно від клінічної форми захворювання та встановити їх патогенетичну роль у розвитку інфекції сечовивідних шляхів. **Матеріали та методи.** Групи дослідження становили 84 дитини (середній вік — 10,0 ± 1,3 року). Основну групу розділили на підгрупи: 1-ша — 17 дітей, хворих на гострий пієлонефрит, 2-га — 21 пацієнт із хронічним пієлонефритом, 3-тя — 16 дітей, хворих на гострий цистит, 4-та — 10 пацієнтів із неуточненими інфекціями сечовидільної системи. Контрольну групу становили 20 умовно здорових дітей. Досліджували вміст 1,25(OH)₂D₃ та DBP методом імуноферментного аналізу. **Результати.** Встановлено, що розвиток запального процесу в сечовивідних шляхах супроводжувався статистично значущим (p < 0,01) зниженням рівня 1,25(OH)₂D₃ у сироватці

крові дітей основної групи порівняно з контрольною. Уміст 1,25(OH)₂D₃ у пацієнтів усіх підгруп був достовірно нижчим за показники контрольної групи (p < 0,01), проте без статистичної різниці. Рівень DBP у сироватці крові дітей основної групи був статистично значуще (p < 0,05) підвищеним порівняно з контрольною, але статистично значущої різниці між підгрупами, що досліджувалися, ми не виявили. **Висновки.** Розвиток гострого запального процесу в сечовивідних шляхах у дітей відбувається на тлі статистично значущого зниження рівня 1,25(OH)₂D₃ у сироватці крові в поєднанні з високими рівнями вітаміну D-зв'язуючого білка. Це виступає патогенетичним підґрунтям необхідності розробки терапевтичних і профілактичних схем призначення вітаміну D дітям з інфекціями сечовидільної системи.

Ключові слова: діти; інфекція сечовивідних шляхів; вітамін D; вітамін D-зв'язуючий білок